Last Updated: May 12, 2026

Claims for Patent: 8,318,441

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,318,441

Title:	Fibrinogen alpha and hemoglobin polypeptides as cancer markers
Abstract:	The present invention provides methods of detecting cancer using biomarkers.
Inventor(s):	Miron; Alexander (Chestnut Hill, MA), Iglehart; James Dirk (Newton, MA), Harris; Lyndsay N. (Madison, CT), Lu; Xin (Cambridge, MA), Shi; Qian (Brighton, MA)
Assignee:	Dana-Farber Cancer Institute, Inc. (Boston, MA)
Application Number:	12/753,527
Patent Claims:	1. A method for facilitating the diagnosis of a breast cancer in a subject, comprising detecting a fibrinogen .alpha.C domain polypeptide consisting of SEQ ID No. 1, from a blood sample from said subject, wherein a decrease of said polypeptide in said sample compared to a normal control sample indicates the presence of breast cancer in said subject. 2. The method of claim 1, wherein said subject has previously been treated surgically or hormonally for said cancer. 3. The method of claim 1, further comprising detecting Alpha-fetoprotein (AFP), Beta-2-microglobulin (B2M), Bladder tumor antigen (BTA), CA 15-3, CA 27.29, CA 125, CA 72-4, CA 19-9, Calcitonin, Carcinoembryonic antigen (CEA), Chromogranin A, Serum gamma globulin, Serum Her-2/neu, Human chorionic gonadotropin (HCG), Lipid Associated Sialic Acid in Plasma (LASA-P), NMP22, Neuron-specific enolase (NSE), Prostate-specific antigen (PSA), Prostatic acid phosphatase (PAP), Prostate-specific membrane antigen (PSMA), S-IOO, TA-90, Thyroglobulin, or Tissue polypeptide antigen (TPA). 4. The method of claim 1, wherein said subject is BRAC1 or BRAC2 positive. 5. The method of claim 1, wherein said cancer is breast cancer, colon cancer, liver cancer, pancreatic cancer, ovarian cancer, prostate cancer, or lung cancer. 6. The method of claim 1, further comprising detecting a peptide with mass to charge (m/z) ratio of about 7558, 7933, 1418 or 15168. 7. The method of claim 1, wherein said fibrinogen .alpha.C domain polypeptide is detected electrophoretically, or immunochemically. 8. The method of claim 7, wherein said immunochemical detection is by radio-immune assay, immunofluorescence assay or by an enzyme-linked immunosorbant assay. 9. A method according to claim 1, wherein said subject has not been previously diagnosed as having cancer. 10. A method according to claim 1, wherein said subject has been previously diagnosed as having cancer. 11. A method of diagnosing a breast cancer in a subject comprising, detecting the presence of a fibrinogen .alpha.C domain polypeptide consisting of SEQ. ID No: 1 from a blood sample from the subject; determining the level of said fibrinogen .alpha.C domain polypeptide in said sample to provide a test value; and comparing the test value to a standard value, wherein a test value below the standard value is indicative of breast cancer. 12. The method of claim 11, wherein said test value is 2 fold lower than said standard value. 13. The method of claim 11, wherein said test value is 5 fold lower than said standard value. 14. The method of claim 11, wherein said test value is 10 fold lower than said standard value. 15. The method of claim 1, wherein said polypeptide is detected electrophoretically, or immunochemically.

Details for Patent 8,318,441

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	8,318,441	2030-04-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	8,318,441	2030-04-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	8,318,441	2030-04-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	8,318,441	2030-04-02
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	8,318,441	2030-04-02
Ferring Pharmaceuticals Inc.	A.P.L.	chorionic gonadotropin	For Injection	017055	December 13, 1974	8,318,441	2030-04-02
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973	8,318,441	2030-04-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.